Late Cardiac Effects in Childhood Cancer Survivors

Steven E Lipshultz, N. Patel, V. I. Franco, S. Fisher

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Within the first 30 years after cancer diagnosis, survivors of childhood cancers have an estimated 75% cumulative incidence of treatment-related chronic health problems. In the United States, where 1 in 680 people between 20 and 50 years old are survivors of childhood cancer, the impact of long-term health consequences is concerning, particularly because this population is growing. Cancer treatment-related cardiotoxicity is the leading noncancer cause of morbidity, and after 30 years, exceeds the mortality rates of cancer recurrence. Cumulative anthracycline chemotherapy dose received is one of the major risk factors. Others include female sex, younger age at diagnosis, and now emerging genetic mutations. However, evidence-based guidelines to identify and monitor cardiotoxicity are lacking. Dexrazoxane provides cardioprotective benefits in children with high-risk cancers, but additional preventive strategies are still needed. An improved understanding of the lifetime cardiovascular risk associated with these factors in long-term childhood cancer survivors may help guide treatment and predict any potential additional cardiovascular risk of specific cancer therapies, such as anthracyclines.

Original languageEnglish (US)
Title of host publicationCardio-Oncology
Subtitle of host publicationPrinciples, Prevention and Management
PublisherElsevier Inc.
Pages173-186
Number of pages14
ISBN (Electronic)9780128035535
ISBN (Print)9780128035474
DOIs
StatePublished - Dec 15 2016
Externally publishedYes

Fingerprint

Survivors
Neoplasms
Anthracyclines
Dexrazoxane
Second Primary Neoplasms
Health
Therapeutics
Guidelines
Morbidity
Recurrence
Drug Therapy
Mutation
Mortality
Incidence
Population

Keywords

  • Cancer treatment
  • Cardiac late effects
  • Cardiotoxicity
  • Childhood cancer survivors
  • Dexrazoxane

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lipshultz, S. E., Patel, N., Franco, V. I., & Fisher, S. (2016). Late Cardiac Effects in Childhood Cancer Survivors. In Cardio-Oncology: Principles, Prevention and Management (pp. 173-186). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-803547-4.00011-2

Late Cardiac Effects in Childhood Cancer Survivors. / Lipshultz, Steven E; Patel, N.; Franco, V. I.; Fisher, S.

Cardio-Oncology: Principles, Prevention and Management. Elsevier Inc., 2016. p. 173-186.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lipshultz, SE, Patel, N, Franco, VI & Fisher, S 2016, Late Cardiac Effects in Childhood Cancer Survivors. in Cardio-Oncology: Principles, Prevention and Management. Elsevier Inc., pp. 173-186. https://doi.org/10.1016/B978-0-12-803547-4.00011-2
Lipshultz SE, Patel N, Franco VI, Fisher S. Late Cardiac Effects in Childhood Cancer Survivors. In Cardio-Oncology: Principles, Prevention and Management. Elsevier Inc. 2016. p. 173-186 https://doi.org/10.1016/B978-0-12-803547-4.00011-2
Lipshultz, Steven E ; Patel, N. ; Franco, V. I. ; Fisher, S. / Late Cardiac Effects in Childhood Cancer Survivors. Cardio-Oncology: Principles, Prevention and Management. Elsevier Inc., 2016. pp. 173-186
@inbook{e412993c2113488cb29dbfe19e3cb0ab,
title = "Late Cardiac Effects in Childhood Cancer Survivors",
abstract = "Within the first 30 years after cancer diagnosis, survivors of childhood cancers have an estimated 75{\%} cumulative incidence of treatment-related chronic health problems. In the United States, where 1 in 680 people between 20 and 50 years old are survivors of childhood cancer, the impact of long-term health consequences is concerning, particularly because this population is growing. Cancer treatment-related cardiotoxicity is the leading noncancer cause of morbidity, and after 30 years, exceeds the mortality rates of cancer recurrence. Cumulative anthracycline chemotherapy dose received is one of the major risk factors. Others include female sex, younger age at diagnosis, and now emerging genetic mutations. However, evidence-based guidelines to identify and monitor cardiotoxicity are lacking. Dexrazoxane provides cardioprotective benefits in children with high-risk cancers, but additional preventive strategies are still needed. An improved understanding of the lifetime cardiovascular risk associated with these factors in long-term childhood cancer survivors may help guide treatment and predict any potential additional cardiovascular risk of specific cancer therapies, such as anthracyclines.",
keywords = "Cancer treatment, Cardiac late effects, Cardiotoxicity, Childhood cancer survivors, Dexrazoxane",
author = "Lipshultz, {Steven E} and N. Patel and Franco, {V. I.} and S. Fisher",
year = "2016",
month = "12",
day = "15",
doi = "10.1016/B978-0-12-803547-4.00011-2",
language = "English (US)",
isbn = "9780128035474",
pages = "173--186",
booktitle = "Cardio-Oncology",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Late Cardiac Effects in Childhood Cancer Survivors

AU - Lipshultz, Steven E

AU - Patel, N.

AU - Franco, V. I.

AU - Fisher, S.

PY - 2016/12/15

Y1 - 2016/12/15

N2 - Within the first 30 years after cancer diagnosis, survivors of childhood cancers have an estimated 75% cumulative incidence of treatment-related chronic health problems. In the United States, where 1 in 680 people between 20 and 50 years old are survivors of childhood cancer, the impact of long-term health consequences is concerning, particularly because this population is growing. Cancer treatment-related cardiotoxicity is the leading noncancer cause of morbidity, and after 30 years, exceeds the mortality rates of cancer recurrence. Cumulative anthracycline chemotherapy dose received is one of the major risk factors. Others include female sex, younger age at diagnosis, and now emerging genetic mutations. However, evidence-based guidelines to identify and monitor cardiotoxicity are lacking. Dexrazoxane provides cardioprotective benefits in children with high-risk cancers, but additional preventive strategies are still needed. An improved understanding of the lifetime cardiovascular risk associated with these factors in long-term childhood cancer survivors may help guide treatment and predict any potential additional cardiovascular risk of specific cancer therapies, such as anthracyclines.

AB - Within the first 30 years after cancer diagnosis, survivors of childhood cancers have an estimated 75% cumulative incidence of treatment-related chronic health problems. In the United States, where 1 in 680 people between 20 and 50 years old are survivors of childhood cancer, the impact of long-term health consequences is concerning, particularly because this population is growing. Cancer treatment-related cardiotoxicity is the leading noncancer cause of morbidity, and after 30 years, exceeds the mortality rates of cancer recurrence. Cumulative anthracycline chemotherapy dose received is one of the major risk factors. Others include female sex, younger age at diagnosis, and now emerging genetic mutations. However, evidence-based guidelines to identify and monitor cardiotoxicity are lacking. Dexrazoxane provides cardioprotective benefits in children with high-risk cancers, but additional preventive strategies are still needed. An improved understanding of the lifetime cardiovascular risk associated with these factors in long-term childhood cancer survivors may help guide treatment and predict any potential additional cardiovascular risk of specific cancer therapies, such as anthracyclines.

KW - Cancer treatment

KW - Cardiac late effects

KW - Cardiotoxicity

KW - Childhood cancer survivors

KW - Dexrazoxane

UR - http://www.scopus.com/inward/record.url?scp=85022002507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022002507&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-803547-4.00011-2

DO - 10.1016/B978-0-12-803547-4.00011-2

M3 - Chapter

SN - 9780128035474

SP - 173

EP - 186

BT - Cardio-Oncology

PB - Elsevier Inc.

ER -